Brussels (Belgium) - June 13, 2006: 1:00 pm CET - “2006 should be another year of continued solid sales growth as well as substantial re-investment in UCB’s promising future driven by Cimzia™ and a pipeline of potential new products. We intend to continue our growth through our solid R&D pipeline. A detailed update of our R&D progress will be provided at the UCB R&D days in September 2006 (London: September 26 and New York: September 28). In addition to our organic growth, we are exploring opportunities for targeted acquisitions that fit our strategy and financial goals. UCB’s acquisition of Epratuzumab, a specialist product for auto-immune diseases (such as Systemic Lupus Erythematosus, a severe disease with no new treatment for several years), is a recent example. Recent divestments of non-core activities and products generated cash as well as capital gains, which better position us to combine external and internal growth efforts.
